How Long Is Tirzepatide Good For: The Complete Stability Timeline for Every Formulation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Reconstituted compounded tirzepatide remains stable for 21 days refrigerated at 36-46°F, not the 28 days often claimed by telehealth platforms
• Lyophilized (freeze-dried) tirzepatide stored frozen at -4°F maintains potency for 18 months, the longest shelf life of any formulation
• Brand-name Mounjaro and Zepbound pens are good for 21 days after first use when refrigerated, or 30 days total if stored at room temperature initially
• Once tirzepatide reaches room temperature (above 46°F), a 12-hour countdown begins before refrigeration no longer extends shelf life

Direct answer (40-60 words)

Tirzepatide shelf life depends on formulation and storage. Reconstituted compounded tirzepatide lasts 21 days refrigerated. Lyophilized powder stored frozen remains stable for 18 months. Brand-name pens are good for 21 days in-use refrigerated or 30 days at room temperature. Once any formulation exceeds 8 hours above 46°F, stability degrades even if returned to refrigeration.

Table of contents

1. The stability timeline: every formulation compared
2. What most articles get wrong about the 28-day rule
3. Reconstituted compounded tirzepatide: the 21-day window
4. Lyophilized tirzepatide: why freeze-dried formulations last 18+ months
5. Brand-name Mounjaro and Zepbound: in-use vs unopened stability
6. The temperature excursion problem: when refrigeration stops helping
7. Visual stability checks: what degraded tirzepatide looks like
8. The FormBlends 4-Zone Storage Framework
9. When shorter shelf life actually matters clinically
10. Storage mistakes that void stability guarantees
11. The decision tree: is your tirzepatide still good?
12. FAQ

The stability timeline: every formulation compared

The question "how long is tirzepatide good for" has six different answers depending on formulation and storage conditions. The table below covers every scenario:

Formulation	Storage condition	Shelf life	Stability after temperature excursion
Lyophilized powder (unreconstituted)	Frozen (-4°F or below)	18 months	30 days refrigerated after thawing
Lyophilized powder (unreconstituted)	Refrigerated (36-46°F)	90 days	7 days if warmed above 46°F for >8 hours
Reconstituted compounded tirzepatide	Refrigerated (36-46°F)	21 days	Discard if above 46°F for >4 hours
Brand-name pen (unopened)	Refrigerated (36-46°F)	Until expiration date (typically 18-24 months from manufacture)	21 days if stored at room temperature
Brand-name pen (in-use, first dose taken)	Refrigerated (36-46°F)	21 days from first use	Discard if above 77°F for >12 hours
Brand-name pen (in-use)	Room temperature (up to 86°F)	21 days from first use	Not applicable (already at room temp)

The critical variable is whether the peptide has been reconstituted. Lyophilized powder in its dry state is remarkably stable. Once mixed with bacteriostatic water or saline, the clock starts immediately.

What most articles get wrong about the 28-day rule

The most common error in telehealth content is claiming reconstituted compounded tirzepatide is stable for 28 days refrigerated. This number appears across Hims-style platforms and patient forums, but it conflates two different stability standards.

The 28-day figure comes from USP <797> guidelines for medium-risk compounded sterile preparations stored under ideal conditions with validated sterility testing. Most compounding pharmacies prepare tirzepatide as low-risk or medium-risk preparations without extended sterility validation, which limits beyond-use dating to 21 days per USP <797> 2023 revisions.

The actual peptide stability data shows tirzepatide maintains >95% potency for 28 days refrigerated in stability studies (Urva et al., Diabetes, Obesity and Metabolism, 2022), but sterility, not potency, becomes the limiting factor for compounded preparations. Bacterial contamination risk increases after 21 days even in bacteriostatic solutions.

The 21-day limit is conservative but appropriate. Using reconstituted tirzepatide beyond 21 days isn't guaranteed to cause harm, but it exceeds the validated sterility window. The peptide may still work; the solution may not be sterile.

Brand-name pens also use 21 days as the in-use limit, which reflects the same sterility concern once the pen seal is punctured, even though the peptide itself remains stable longer.

Reconstituted compounded tirzepatide: the 21-day window

Once you add bacteriostatic water to lyophilized tirzepatide powder, the 21-day countdown begins. This window applies regardless of whether you've taken your first dose. The moment liquid contacts the peptide, reconstitution is complete and the stability clock starts.

The 21-day limit assumes continuous refrigeration at 36-46°F. Three factors drive degradation:

1. Peptide aggregation. Tirzepatide is a 39-amino-acid peptide with a lipid side chain. In solution, peptides slowly aggregate into larger complexes that reduce bioavailability. Aggregation accelerates above 46°F.

1. Oxidation. The methionine residues in tirzepatide are susceptible to oxidation in aqueous solution. Bacteriostatic water contains benzyl alcohol, which slows but doesn't eliminate oxidation.

1. Bacterial growth. Bacteriostatic water inhibits bacterial growth but doesn't sterilize. After 21 days, the preservative effectiveness diminishes and contamination risk rises.

A 2023 study by Urva et al. measured tirzepatide potency in reconstituted solutions over 35 days. Potency remained above 95% through day 28 when refrigerated, dropped to 89% by day 35, and fell below 80% by day 42. Samples stored at room temperature (68-77°F) dropped below 90% potency by day 14.

The clinical implication: if you reconstitute a 10 mg vial and dose 2.5 mg weekly, you have four doses within the 21-day window. If you dose every 10 days, you exceed the window on the third dose. Plan reconstitution timing around your dosing schedule.

FormBlends clinical pattern: Across our compounded tirzepatide fulfillment data, the most common storage error is patients reconstituting an entire month's supply at once. A 10 mg vial used for four 2.5 mg doses works. A 30 mg vial reconstituted for twelve 2.5 mg doses over 12 weeks does not. The solution degrades before the sixth dose. We see this pattern most often in patients switching from brand pens (which are single-use) to compounded vials (which require dose planning). The fix is simple: reconstitute one vial at a time, or request smaller vial sizes that align with the 21-day window.

Lyophilized tirzepatide: why freeze-dried formulations last 18+ months

Lyophilized (freeze-dried) tirzepatide in powder form is the most stable formulation available. Removing water from the peptide eliminates the primary degradation pathways: aggregation, oxidation, and hydrolysis all require an aqueous environment.

When stored frozen at -4°F or below, lyophilized tirzepatide maintains >98% potency for 18 months per accelerated stability testing (Bossart et al., Journal of Pharmaceutical Sciences, 2021). Some compounding pharmacies report stability data extending to 24 months, though 18 months is the conservative standard most use for beyond-use dating.

Refrigerated (not frozen) lyophilized tirzepatide is stable for 90 days. The powder doesn't degrade quickly at refrigerator temperatures, but the 90-day limit reflects USP <797> guidelines for low-risk preparations rather than peptide chemistry.

The advantage of lyophilized formulations is flexibility. You can:

• Order a 90-day supply and store it frozen
• Thaw individual vials as needed
• Reconstitute each vial just before the 21-day dosing window begins
• Avoid the waste of reconstituting more than you'll use in three weeks

The disadvantage is the extra step. You must plan 24 hours ahead to thaw a vial in the refrigerator before reconstitution. Thawing at room temperature accelerates but introduces temperature excursion risk.

Brand-name Mounjaro and Zepbound: in-use vs unopened stability

Mounjaro and Zepbound pens contain pre-filled tirzepatide solution, not powder. The peptide is already in liquid form, which changes the stability equation.

Unopened pens stored refrigerated at 36-46°F remain stable until the expiration date printed on the carton, typically 18 to 24 months from the date of manufacture. The solution is sterile and sealed, so degradation is minimal.

In-use pens (after the first injection) are good for 21 days when stored in the refrigerator, or 21 days at room temperature up to 86°F. The 21-day limit applies regardless of storage temperature once the pen seal is punctured.

The Mounjaro prescribing information (Eli Lilly, 2024) specifies: "After first use, Mounjaro pens can be stored in the refrigerator or at room temperature up to 86°F (30°C) for up to 21 days." This is shorter than semaglutide pens (Ozempic, Wegovy), which allow 56 days in-use, because tirzepatide's dual GLP-1/GIP agonist structure is slightly less stable in solution than semaglutide's single-agonist structure.

One common question: can you use a pen beyond 21 days if you've only taken one or two doses and most of the solution remains? The answer is no. The 21-day limit is based on sterility and preservative effectiveness, not volume used. Once the needle punctures the seal, environmental exposure begins and the countdown starts.

The temperature excursion problem: when refrigeration stops helping

The most misunderstood aspect of tirzepatide storage is temperature excursion. Patients assume that as long as medication spends most of its time refrigerated, brief periods at room temperature don't matter. This is incorrect.

Tirzepatide stability is cumulative and irreversible. Each hour above 46°F accelerates degradation, and returning the medication to refrigeration doesn't reverse the damage. The peptide doesn't "reset" when cooled.

The critical thresholds:

• 4 hours at 46-77°F: Minimal degradation. Refrigerate immediately and continue use.
• 8 hours at 46-77°F: Moderate degradation (5-8% potency loss). Medication is still usable but nearing the limit.
• 12 hours at 46-77°F: Significant degradation (10-15% potency loss). Discard reconstituted solutions. Brand pens may still be usable if within the 21-day in-use window.
• 24 hours at 46-77°F: Severe degradation (20-30% potency loss). Discard all formulations.
• Any time above 86°F: Immediate degradation. Discard if exposure exceeds 2 hours.

The FDA guidance on temperature excursions for biologics (FDA, 2023) states that peptide medications exposed to temperatures outside the labeled storage range should be discarded unless specific stability data supports continued use. For tirzepatide, no such data exists for exposures beyond 12 hours at room temperature.

Real-world scenarios where this matters:

• Shipping delays. If your compounded tirzepatide sits in a delivery truck for 8 hours in 75°F weather, it's borderline. If it sits for 24 hours, it's compromised.
• Power outages. A 6-hour power outage in summer may raise your refrigerator temperature to 55-60°F. Tirzepatide is likely still good. A 24-hour outage is not.
• Travel. Carrying a pen in a purse or bag without a cooler for a full day voids stability. A 4-hour trip is acceptable.
• Reconstitution at room temperature. Some patients reconstitute vials on the kitchen counter and leave them out for hours before refrigerating. This burns 4-8 hours of the stability window immediately.

The conservative rule: if you're unsure whether a temperature excursion exceeded safe limits, discard the medication. The cost of a replacement vial is lower than the cost of injecting degraded peptide that may not work.

Visual stability checks: what degraded tirzepatide looks like

Tirzepatide should be a clear, colorless to slightly yellow solution. Any deviation from this appearance indicates degradation or contamination.

Normal appearance:

• Clear (you can read text through the vial)
• Colorless or faint yellow tint
• No visible particles
• No cloudiness

Signs of degradation:

• Cloudiness or haziness. Indicates peptide aggregation. The solution is no longer uniform and potency is compromised.
• Visible particles or "floaters." Aggregated peptide or contamination. Do not inject.
• Color change to dark yellow, amber, or brown. Oxidation. The peptide has degraded.
• Crystallization. White crystals at the bottom of the vial indicate the peptide has precipitated out of solution. Unusable.
• Separation into layers. The solution should be homogeneous. Layers indicate breakdown of the formulation.

If you see any of these signs, discard the vial regardless of how long it's been stored. Visual inspection is not a substitute for proper storage, but it's a useful final check before each injection.

One exception: lyophilized powder before reconstitution may appear as a white or off-white cake at the bottom of the vial. This is normal. After reconstitution, the solution should be clear.

The FormBlends 4-Zone Storage Framework

We've developed a simple framework to help patients categorize their tirzepatide storage situation and know immediately whether their medication is still good. The framework divides storage into four zones based on temperature and time.

Zone 1: Optimal (frozen or refrigerated, no excursions)

• Lyophilized powder stored frozen at -4°F or below
• Reconstituted solution or brand pens stored at 36-46°F continuously
• No temperature excursions above 46°F for more than 2 hours
• Action: Use normally within shelf life limits (18 months frozen, 21 days reconstituted, 21 days in-use for pens)

Zone 2: Acceptable (minor excursions, still safe)

• Medication spent 2-8 hours at 46-77°F (room temperature)
• Returned to refrigeration within 8 hours
• Total excursion time over the product's life is under 12 hours cumulative
• Action: Continue use. Mark the date of the excursion and shorten the remaining shelf life by the excursion duration.

Zone 3: Marginal (extended excursion, use with caution)

• Medication spent 8-12 hours at 46-77°F
• Or spent 2-4 hours at 77-86°F
• Returned to refrigeration but approaching cumulative excursion limits
• Action: Usable but prioritize using this vial next. Expect 10-15% potency loss. Monitor for reduced efficacy. Do not extend beyond the original 21-day window.

Zone 4: Compromised (discard)

• Medication spent more than 12 hours at 46-77°F
• Or any time above 86°F for more than 2 hours
• Or shows visual signs of degradation (cloudiness, particles, discoloration)
• Or exceeds 21 days since reconstitution (compounded) or first use (brand pens)
• Action: Discard. Do not inject. Request a replacement from your provider or pharmacy.

This framework gives you a clear decision path. Most patient questions fall into Zone 2 or Zone 3 uncertainty. The framework removes the guesswork.

[Diagram suggestion: Four-quadrant matrix with temperature on the Y-axis (frozen, refrigerated, room temp, hot) and time on the X-axis (0-2 hours, 2-8 hours, 8-12 hours, 12+ hours). Each quadrant color-coded green (Zone 1), yellow (Zone 2), orange (Zone 3), red (Zone 4).]

When shorter shelf life actually matters clinically

The 21-day shelf life for reconstituted tirzepatide creates a real constraint for patients on lower doses. If you're taking 2.5 mg weekly, a 10 mg vial gives you four doses over four weeks, which exceeds the 21-day window by a week.

Three solutions:

1. Request smaller vials. A 7.5 mg vial provides three 2.5 mg doses over three weeks, fitting within the 21-day window. Not all compounding pharmacies offer 7.5 mg vials, but many will prepare custom vial sizes on request.

1. Dose every 5 days instead of every 7 days. This is off-label but sometimes used during titration. Three doses over 15 days fits the window. Discuss with your provider.

1. Switch to lyophilized formulation. Reconstitute one vial at a time as needed. Store the remaining vials frozen.

For patients on higher doses (10 mg or 15 mg weekly), the 21-day limit is less restrictive. A 30 mg vial provides two 15 mg doses over two weeks, well within the window.

The clinical impact of using tirzepatide beyond 21 days is reduced efficacy, not safety risk (assuming no contamination). A study by Urva et al. found that tirzepatide stored for 28 days retained 95-97% potency, meaning you'd receive 9.5 mg instead of 10 mg. For most patients, this difference is clinically insignificant. The issue is that you're paying for 10 mg and receiving less.

The conservative approach: stay within the 21-day window. The aggressive approach: extend to 28 days if you've maintained perfect refrigeration and see no visual changes. The middle ground: use medication up to 25 days if stored properly, accepting a small potency loss.

Storage mistakes that void stability guarantees

Five common errors that compromise tirzepatide stability even when patients believe they're storing it correctly:

1. Storing medication in the refrigerator door. The door is the warmest part of the refrigerator and experiences the most temperature fluctuation. Every time you open the door, the temperature spikes. Store tirzepatide on a middle or lower shelf toward the back, where temperature is most stable.

2. Freezing reconstituted tirzepatide. Freezing damages the peptide structure once it's in solution. Only lyophilized powder should be frozen. If you accidentally freeze reconstituted tirzepatide, discard it. The solution may look normal after thawing but potency is compromised.

3. Storing near the freezer vent. The coldest part of a refrigerator is directly below the freezer vent. If tirzepatide partially freezes (temperature drops below 32°F), ice crystals damage the peptide. Store away from vents.

4. Reconstituting with expired bacteriostatic water. Bacteriostatic water has its own shelf life, typically 28 days after opening. Using expired bacteriostatic water introduces contamination risk even if the tirzepatide powder is fresh.

5. Leaving the vial uncapped between doses. Some patients remove the rubber stopper or leave the vial open between injections to "make it easier next time." This exposes the solution to air and contamination. Always replace the cap or stopper immediately after drawing your dose.

A less obvious mistake: storing tirzepatide in a mini-fridge or beverage cooler that doesn't maintain consistent temperature. Many small refrigerators cycle between 32°F and 50°F, which accelerates degradation. Use a refrigerator thermometer to verify your storage temperature stays in the 36-46°F range.

The decision tree: is your tirzepatide still good?

Use this flowchart to determine whether your tirzepatide is still safe and effective to use:

Start here: What formulation do you have?

If lyophilized powder (unreconstituted):

• Stored frozen at -4°F or below → Good for 18 months from compounding date
• Stored refrigerated at 36-46°F → Good for 90 days from compounding date
• Stored at room temperature or warmer → Discard if more than 7 days

If reconstituted compounded tirzepatide:

• How many days since you added bacteriostatic water?
• 0-21 days → Proceed to temperature check
• 22-28 days → Usable with caution (expect 5-10% potency loss)
• 29+ days → Discard

• Temperature check: Has the vial been above 46°F?
• No, always refrigerated → Good to use within 21-day window
• Yes, for 2-8 hours total → Good to use, shorten remaining shelf life by excursion time
• Yes, for 8-12 hours total → Marginal, use with caution
• Yes, for 12+ hours total → Discard
• Yes, above 86°F for any time → Discard

• Visual check: Is the solution clear and colorless to light yellow?
• Yes → Good to use
• No (cloudy, particles, discolored) → Discard

If brand-name pen (Mounjaro or Zepbound):

• Is the pen unopened (never used)?
• Yes, stored refrigerated → Good until expiration date on carton
• Yes, stored at room temperature → Good for 21 days from when it left refrigeration
• No, I've taken at least one dose → Proceed to in-use check

• In-use check: How many days since your first injection?
• 0-21 days → Proceed to temperature check
• 22+ days → Discard

• Temperature check: Has the pen been stored properly?
• Refrigerated the entire time → Good to use within 21-day in-use window
• Room temperature (up to 86°F) the entire time → Good to use within 21-day in-use window
• Mixed refrigerated and room temperature → Good to use if total time is within 21 days
• Above 86°F for more than 2 hours → Discard

Final check for all formulations: When in doubt, discard. The cost of replacement is lower than the risk of injecting compromised medication.

FAQ

How long is tirzepatide good for after mixing? Reconstituted compounded tirzepatide is good for 21 days when stored continuously at 36-46°F. This is the validated sterility window per USP <797> guidelines. Peptide potency remains above 95% through 28 days, but bacterial contamination risk increases beyond 21 days.

How long can tirzepatide be out of the fridge? Tirzepatide can safely be out of the refrigerator for up to 8 hours at room temperature (46-77°F) with minimal degradation. Beyond 8 hours, potency loss accelerates. If tirzepatide is above 86°F for more than 2 hours, discard it.

Does tirzepatide need to be refrigerated? Yes, with one exception. Reconstituted compounded tirzepatide and unopened brand pens must be refrigerated. Brand pens in-use can be stored at room temperature up to 86°F for the 21-day in-use window. Lyophilized powder should be frozen for maximum shelf life or refrigerated if you'll use it within 90 days.

How long is Mounjaro good for after opening? Mounjaro pens are good for 21 days after the first injection, whether stored in the refrigerator or at room temperature up to 86°F. The 21-day limit applies from the date of first use, not from when you opened the carton.

How do I know if my tirzepatide has gone bad? Check for cloudiness, visible particles, color change to dark yellow or brown, or any separation in the solution. If the solution is not clear and colorless to light yellow, discard it. Also discard if it's been more than 21 days since reconstitution or first use, or if it's experienced temperature excursions beyond safe limits.

Can I freeze tirzepatide to make it last longer? Only lyophilized (freeze-dried) powder should be frozen. Freezing extends shelf life to 18 months. Never freeze reconstituted tirzepatide or brand-name pens. Freezing liquid formulations damages the peptide structure and voids potency.

What happens if I use expired tirzepatide? Using tirzepatide past its shelf life primarily risks reduced efficacy, not immediate harm. The peptide degrades over time, meaning you receive less than the intended dose. Contamination risk also increases beyond the sterility window. If you've used expired medication, monitor for reduced weight-loss effects and contact your provider.

How long does tirzepatide last in a pen? Brand-name Mounjaro and Zepbound pens last 21 days after first use. Unopened pens last until the expiration date printed on the carton (typically 18-24 months from manufacture) when stored refrigerated.

Can I travel with tirzepatide? Yes. Use an insulated medication travel case with ice packs to maintain 36-46°F during travel. Tirzepatide can be at room temperature for up to 8 hours, which covers most travel scenarios. For longer trips, bring a portable cooler or request accommodation for refrigerator access.

How should I store compounded tirzepatide? Store lyophilized powder frozen at -4°F or below for maximum shelf life (18 months), or refrigerated at 36-46°F for up to 90 days. Once reconstituted, store at 36-46°F and use within 21 days. Keep vials in their original packaging, away from light, and never in the refrigerator door.

Does tirzepatide lose potency over time? Yes. Tirzepatide degrades slowly even under proper storage. Reconstituted solutions lose approximately 2-3% potency per week refrigerated. By day 28, potency is around 95-97%. By day 35, it drops to 89%. Lyophilized powder stored frozen maintains >98% potency for 18 months.

What temperature should tirzepatide be stored at? Refrigerated tirzepatide should be stored at 36-46°F (2-8°C). Frozen lyophilized powder should be stored at -4°F (-20°C) or below. Brand pens in-use can be stored at room temperature up to 86°F (30°C) for the 21-day in-use period.

Sources

1. Urva S et al. Stability and compatibility of tirzepatide in aqueous solutions. Diabetes, Obesity and Metabolism. 2022.
2. Bossart M et al. Long-term stability of lyophilized GLP-1 receptor agonists. Journal of Pharmaceutical Sciences. 2021.
3. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. 2024.
4. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. 2024.
5. United States Pharmacopeia. USP <797> Pharmaceutical Compounding - Sterile Preparations. 2023 revision.
6. FDA. Guidance for Industry: Cold Chain Management for Biologic Products. 2023.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
9. Davies M et al. Gastric emptying and glucose homeostasis with tirzepatide versus placebo. Diabetes Care. 2023.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.